Summary
In the phase 2 trial published in the [[New England Journal of Medicine|https://www.nejm.org/doi/full/10.1056/NEJMoa2301972]] in 2023, 338 adults with obesity received retatrutide or placebo by weekly injection under medical supervision for 48 weeks. Weight reduction rose with dose. The highest dose group reached a mean reduction of 24.2% at 48 weeks, against 2.1% with placebo.
This page describes published trial results. It is not dosing guidance and does not apply to laboratory research materials.
What a dose response means
A dose response describes how an effect changes as the amount of a compound changes. A clear dose response, where higher doses give larger effects, is usually taken as evidence that the effect is caused by the compound. Trials also use it to find a dose that balances benefit and tolerability, which is why most trials test several dose levels rather than one.
What the phase 2 trial found
The trial compared dose groups with placebo. Mean weight change at 24 and 48 weeks was:
- Placebo: 1.6% and 2.1% reduction.
- 1 mg: 7.2% and 8.7%.
- 4 mg combined: 12.9% and 17.1%.
- 8 mg combined: 17.3% and 22.8%.
- 12 mg: 17.5% and 24.2%.
The curve was clearly dose dependent. The gain from 8 mg to 12 mg was small compared with the gain from 1 mg to 4 mg. At 24 weeks the 12 mg group was close to the 8 mg group, and weight was still falling at the end of the study in the higher dose groups.
How many people reached weight loss thresholds
The paper also reported the share of participants who lost at least 5%, 10% and 15% of body weight at 48 weeks. In the 12 mg group these were 100%, 93% and 83%. In the 1 mg group they were 64%, 27% and 16%, and with placebo 27%, 9% and 2%. These threshold figures show the spread across individuals, not only the average.
Why trials use dose escalation
Participants did not start at the top dose. Doses were stepped up every 4 weeks for up to 12 weeks. The phase 2 trial compared groups starting at 2 mg and 4 mg and found that the lower starting dose partly reduced gastrointestinal events. Nausea and related effects are common with this class of peptides and are generally more frequent early on and at higher doses, so gradual escalation is used to improve tolerability. See [[retatrutide side effects reported in trials|/blog/retatrutide-side-effects-trials]].
Phase 3 results
Eli Lilly announced phase 3 results in July 2026. Both trials lasted 80 weeks, and the figures below use the efficacy estimand, which describes the effect in people who took treatment as intended.
- TRIUMPH-2 (adults with type 2 diabetes and obesity or overweight, 1,152 participants): 12.7% at 4 mg, 19.1% at 9 mg and 20.8% at 12 mg, against 4.0% with placebo.
- TRIUMPH-3 (adults with severe obesity and established cardiovascular disease, 1,949 participants): 21.6% at 9 mg and 22.6% at 12 mg, against 3.2% with placebo.
The pattern matches phase 2. The step from 9 mg to 12 mg was small, while 4 mg gave a clearly lower result. The trials had different populations and lengths, so the numbers should not be compared directly with phase 2. See [[trial results explained|/blog/retatrutide-trial-results]].
What the placebo groups show
Placebo groups also lose some weight, because trial participants usually receive lifestyle support. Placebo reduction was 2.1% at 48 weeks in phase 2, 4.0% in TRIUMPH-2 and 3.2% in TRIUMPH-3. The useful number is the difference between a dose group and its own placebo group, not the raw percentage on its own. Trials with longer duration, different populations and different background care will not give the same placebo figure.
Weight change over time
The phase 2 results show how the effect builds. In the 12 mg group the mean reduction was 17.5% at 24 weeks and 24.2% at 48 weeks, so about seven further percentage points were lost in the second half of the trial. The phase 3 trials ran for 80 weeks, so they cover a longer period than phase 2. Reading only a single time point hides the shape of the curve.
How to read dose figures
Check whether a percentage refers to everyone assigned to treatment or only those who stayed on it, how long the trial ran and who took part. A figure at 24 weeks and a figure at 48 or 80 weeks are different things. Sponsor news releases give headline numbers first, and the peer reviewed papers are the place to check methods.
What this does not cover
Trial doses relate to an investigational medicine given under supervision. They say nothing about research materials supplied for laboratory use, and Cambridge Health does not give dosing advice for use in people. Retatrutide is not licensed in the UK. See [[the regulatory position|/blog/is-retatrutide-legal-uk]].
References and evidence context
Eli Lilly, retatrutide phase 3 TRIUMPH-2 and TRIUMPH-3 results, news release, 23 July 2026
Figures are as reported in the sources named at the time of writing. Phase 3 figures come from the sponsor news release, so check the peer reviewed papers for full methods and safety tables when published. This is general information about published research, not medical advice.
Frequently asked questions
What doses were tested in the retatrutide phase 2 trial?
Placebo, 1 mg, 4 mg, 8 mg and 12 mg groups, with different starting doses in some groups. Check the NEJM paper for the full schedule.
Does a higher dose always mean more weight loss?
In the phase 2 trial weight reduction rose with dose, but the gain flattened at the upper end. Higher doses also carried more gastrointestinal side effects.
What did the phase 3 trials test?
TRIUMPH-2 tested 4 mg, 9 mg and 12 mg and TRIUMPH-3 tested 9 mg and 12 mg, each against placebo for 80 weeks.
Is this dosing advice?
No. It summarises published trial data on an investigational medicine and is not medical advice.
Important information
Research use only. Not a medicine, not a supplement, not approved for human or animal use.
Cambridge Health™ does not provide usage, dosage, reconstitution or administration guidance for any product. Product information on this page is provided for research and educational context only.
- Supplied strictly for laboratory and analytical research use. Not for human or animal consumption.
- No medical advice, treatment guidance or personal use recommendations are provided.
- Buyers are solely responsible for ensuring that the purchase, import, handling and use of research materials is lawful in their jurisdiction.
Supplied for laboratory research use only. Not a licensed medicine and not approved for human or animal use.
Related
Enquire about research supply
Cambridge Health supplies retatrutide research vials and the RetaPen research pen for laboratory research only.